Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	1230487-00-9
Formula :	C₂₉H₃₅F₃N₂O₃
M.W :	516.60
SMILES Code :	O=C(C1CN(CC2=CC=C(/C(C)=N/OCC3=CC=C(C4CCCCC4)C(C(F)(F)F)=C3)C=C2CC)C1)O
Synonyms :	BAF-312
MDL No. :	MFCD26142651
InChI Key :	KIHYPELVXPAIDH-HNSNBQBZSA-N
Pubchem ID :	44599207

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H320-H335
Precautionary Statements:	P264-P270-P301+P312-P330

Human-induced pluripotent stem cell-derived neural stem/progenitor cells (hiPSCs-NSCs/NPCs)	0.01 nM, 0.1 nM, 0.5 nM, 1.0 nM, 5.0 nM	~6 days	Siponimod/BAF312 at concentrations of 0.1 nM, 0.5 nM, 1.0 nM, and 5.0 nM significantly reduced TNFα-induced apoptosis in hiPSCs-NSCs/NPCs cells, as indicated by decreased green fluorescence from activated caspase-3/7.	Int J Mol Sci. 2024 Feb 20;25(5):2454.
BV2 microglial cells	0.1 µM	1 hour	To assess the effect of Siponimod on the release of IL-6 and RANTES from activated microglial cells. Results showed that Siponimod reduced the release of IL-6 and RANTES from TNF-stimulated BV2 cells.	J Neuroinflammation. 2016 Aug 26;13(1):207.
Rat primary cultured cortical neurons	0.1 nM, 0.5 nM, 1.0 nM	10 days	Siponimod/BAF312 dose-dependently decreased the risk of cortical neuron death with HR 0.84, 0.81, and 0.78 and p values of 0.007, 0.002, and 2×10^-5, respectively.	Int J Mol Sci. 2024 Feb 20;25(5):2454.
Primary rat microglia	10 µM or 50 µM	3 days	To investigate the effects of Siponimod on microglial morphology and actin filament organization in an inflammatory milieu induced by LPS. Results showed that 50 µM Siponimod significantly reduced the LPS-induced increase in mean cell area and altered actin organization.	Int J Mol Sci. 2022 Oct 31;23(21):13278.
Mixed astrocyte/microglia cell cultures	1 µM	60 minutes	To investigate the modulatory effect of Siponimod on proinflammatory responses in mixed glia cell cultures. Results showed that Siponimod did not decrease cytokine release; instead, the concentration of some cytokines (e.g., MCP-1, IL12-p40, G-CSF) was significantly increased.	Proc Natl Acad Sci U S A. 2022 Oct 4;119(40):e2204509119.
mouse microglia	1 nM, 10 nM, 100 nM, 1 μM	18 h	BAF312 moderately attenuated LPS-induced increases in IL6 levels	J Neuroinflammation. 2016 Feb 8;13:31
human astrocytes	1 nM, 10 nM, 100 nM, 1 μM		BAF312 induced ERK and AKT phosphorylation in a concentration-dependent manner	J Neuroinflammation. 2016 Feb 8;13:31
mouse astrocytes	1 nM, 10 nM, 100 nM, 1 μM		BAF312 induced ERK and AKT phosphorylation in a concentration-dependent manner	J Neuroinflammation. 2016 Feb 8;13:31

C57BL/6 mice	Experimental autoimmune encephalomyelitis (EAE)	Continuous intracerebroventricular (icv) infusion	0.45 μg/day	4 weeks	To evaluate the neuroprotective effects of Siponimod in the CNS of EAE mice. Results showed that Siponimod improved EAE clinical scores, reduced microgliosis and astrogliosis, decreased lymphocyte infiltration, and rescued GABAergic transmission deficits and PV+ interneuron loss.	J Neuroinflammation. 2016 Aug 26;13(1):207.
C57BL/6 mice	Collagenase VII-S-induced ICH model	Intraperitoneal and subcutaneous injection	1 mg/kg	First dose 30 minutes after surgery, followed by doses at 24 and 48 hours	Siponimod treatment significantly reduced brain lesion volume and brain edema, and improved long-term neurologic function.	Aging Dis. 2023 Jun 1;14(3):966-991
Lewis rats	Experimental autoimmune neuritis (EAN)	Oral	1.0 mg/kg/day	Daily administration from day 5 to 27 post-immunization	To evaluate the therapeutic effect of Siponimod on EAN. Results showed that Siponimod alleviated symptom severity, reduced the expression of interferon-gamma and IL-10 mRNAs in lymph nodes and CE, and decreased demyelinating lesions and inflammatory cell invasion.	J Neuroinflammation. 2023 Feb 14;20(1):35
Mice	Chronic high intraocular pressure and acute NMDA excitotoxicity models	Oral	10 mg/kg	8 weeks	Siponimod showed neuroprotective effects on the retina and brain in chronic high intraocular pressure and acute NMDA excitotoxicity models, upregulating Akt and Erk1/2 phosphorylation levels through neuronal S1PR1 signaling, and reducing microglial activation and reactive gliosis.	Neural Regen Res. 2023 Apr;18(4):840-848
C57BL/6 mice	NMDA excitotoxicity-induced retinal injury model	Oral	10 mg/kg diet	Continuous administration for 7 days	To evaluate the anti-inflammatory effects of Siponimod in the NMDA excitotoxicity model. Results showed that Siponimod significantly reduced glial activation, suppressed pro-inflammatory pathways, and diminished NLRP3 inflammasome activation and iNOS upregulation.	Mol Neurobiol. 2023 Dec;60(12):7222-7237
Mice	Cuprizone-induced demyelination mouse model	Oral	10 mg/kg food	2 weeks	Siponimod treatment promoted remyelination	Neurol Neuroimmunol Neuroinflamm. 2022 Mar 30;9(3):e1161
New Zealand albino rabbits	Diabetic retinopathy and age-related macular degeneration model	Intravitreal injection	1300 ng or 6500 ng	Single injection, observation time points included 0.5, 1, 2, 4, 6, 8, 10, 16, and 24 hours	To evaluate the pharmacokinetics and toxicity of Siponimod in the vitreous. Results showed that the half-lives of low and high doses of Siponimod were 2.8 h and 3.9 h, respectively, and no signs of toxicity were observed in the retina at 24 h and 7 days.	Mol Pharm. 2024 Jul 1;21(7):3310-3320
Mice	Healthy mice	Oral	133 mg/kg	Single dose	First in vivo fluorine-19 magnetic resonance imaging of the multiple sclerosis drug siponimod, demonstrating drug distribution in the stomach and liver.	Theranostics. 2023 Feb 5;13(4):1217-1234
C57BL/6J mice	Experimental autoimmune encephalomyelitis (EAE)	Oral	20 mg/kg	Ad libitum for 33 days	Evaluated the effects of siponimod on EAE model, showing peripheral lymphopenia but no significant impact on CNS and ENS histopathology	Int J Mol Sci. 2022 Nov 17;23(22):14209
SJL/J mice	Experimental Autoimmune Encephalomyelitis (EAE) model	Oral gavage	3 mg/kg	Daily administration, starting at day 3, 5, or 8 after adoptive transfer	BAF312 treatment significantly ameliorated clinical EAE and diminished subpial pathology, concomitant with a selective reduction in the capacity of transferred T cells to make Th17 cytokines.	JCI Insight. 2020 Jan 16;5(1):e132522
Mice	Chronic experimental autoimmune encephalomyelitis (EAE) model	Oral gavage	3 mg/kg	Once daily for 30 days	To investigate whether siponimod can inhibit the formation of meningeal ectopic lymphoid tissue (mELT). Results showed that siponimod ameliorated the clinical course of EAE and strongly reduced the extent of mELT.	Neurol Neuroimmunol Neuroinflamm. 2021 Dec 15;9(1):e1117
SJL/J mice	TMEV infection model	Oral gavage	3 mg/kg	Daily until euthanasia	To investigate the effect of Siponimod on TMEV-induced neurodegeneration. Results showed that Siponimod treatment worsened clinical disability score (CDS), decreased body weight (BW) and rotarod retention time in TMEV mice, but did not significantly affect most brain region volumes, except for lateral ventricle volume. Siponimod suppressed ventricular enlargement, suggesting reduced TMEV-induced inflammation in LV. No significant differences in spine volume changes were observed between Siponimod- and vehicle-treated animals, but there were differences between HC and TMEV groups, indicating TMEV-induced inflammation contributed to increased spine volume. Spine histology revealed no significant microglial density differences between groups in gray matter, but HC animals had higher type 1 morphology and lower type 2 morphology percentages in gray and white matter regions. This suggests that Siponimod did not significantly affect microglial density but may have modulated neuroinflammation in the spinal cord.	Int J Mol Sci. 2023 Aug 20;24(16):12990
C57BL/6 mice	Cuprizone-induced demyelination model	Oral	3.125 mg/kg	Daily administration for 3 weeks	To investigate the protective effects of Siponimod in the cuprizone-induced demyelination model. Results demonstrated that Siponimod ameliorated cuprizone-induced oligodendrocyte degeneration, demyelination, and axonal injury, and these protective effects were completely absent in S1pr5-deficient mice.	Proc Natl Acad Sci U S A. 2022 Oct 4;119(40):e2204509119.

{[proInfo.proName]}

CAS No.: 1230487-00-9

{[proInfo.proName]}

CAS No.: 1230487-00-9

Alternative Products

Product Details of Siponimod

Safety of Siponimod

Related Pathways of Siponimod

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT03623243	Multiple Sclerosis\|Relapsing M... More >>ultiple Sclerosis\|Advancing Multiple Sclerosis Less <<	PHASE3	COMPLETED	2022-07-06	Novartis Investigative Site, B... More >>irmingham, Alabama, 35209, United States\|Novartis Investigative Site, Cullman, Alabama, 35058, United States\|Alabama Neurology Associates, Homewood, Alabama, 35209, United States\|Novartis Investigative Site, Tucson, Arizona, 85718, United States\|Novartis Investigative Site, Fresno, California, 93710, United States\|Novartis Investigative Site, Fullerton, California, 92835, United States\|Novartis Investigative Site, Irvine, California, 92617, United States\|Novartis Investigative Site, Colorado Springs, Colorado, 80907, United States\|Novartis Investigative Site, Denver, Colorado, 80209, United States\|Novartis Investigative Site, Fort Collins, Colorado, 80528, United States\|Novartis Investigative Site, Boca Raton, Florida, 33487, United States\|Novartis Investigative Site, Bradenton, Florida, 34205, United States\|MS & Neuromuscular Center of Excellence, Clearwater, Florida, 33761, United States\|Novartis Investigative Site, Maitland, Florida, 32751, United States\|Novartis Investigative Site, Miami, Florida, 33136, United States\|Novartis Investigative Site, Ocala, Florida, 34471, United States\|Novartis Investigative Site, Oldsmar, Florida, 34677, United States\|Novartis Investigative Site, Orlando, Florida, 32806, United States\|Novartis Investigative Site, Ormond Beach, Florida, 32174, United States\|Novartis Investigative Site, Sarasota, Florida, 34243, United States\|Novartis Investigative Site, Sunrise, Florida, 33351, United States\|Novartis Investigative Site, Tampa, Florida, 33612, United States\|Novartis Investigative Site, Vero Beach, Florida, 32960, United States\|Novartis Investigative Site, Flossmoor, Illinois, 60422, United States\|Novartis Investigative Site, Indianapolis, Indiana, 46256, United States\|Novartis Investigative Site, Lexington, Kentucky, 40503, United States\|Novartis Investigative Site, Lexington, Kentucky, 40509, United States\|Novartis Investigative Site, Lexington, Kentucky, 40513, United States\|Novartis Investigative Site, Rockville, Maryland, 20854, United States\|Novartis Investigative Site, Clinton Township, Michigan, 48035, United States\|Novartis Investigative Site, Saint Louis, Missouri, 63110, United States\|Novartis Investigative Site, Las Vegas, Nevada, 89128, United States\|Novartis Investigative Site, Hackensack, New Jersey, 07601, United States\|Novartis Investigative Site, Asheville, North Carolina, 28806, United States\|Novartis Investigative Site, Greensboro, North Carolina, 27405, United States\|Novartis Investigative Site, Raleigh, North Carolina, 27607, United States\|Novartis Investigative Site, Cincinnati, Ohio, 45219, United States\|Novartis Investigative Site, Cleveland, Ohio, 44106-5028, United States\|Novartis Investigative Site, Oklahoma City, Oklahoma, 73104, United States\|Abington Neurological Associates, Ltd, Abington, Pennsylvania, 19001, United States\|Novartis Investigative Site, Philadelphia, Pennsylvania, 19141, United States\|Novartis Investigative Site, Willow Grove, Pennsylvania, 19090, United States\|Novartis Investigative Site, Greer, South Carolina, 29650, United States\|Novartis Investigative Site, Indian Land, South Carolina, 29707, United States\|Novartis Investigative Site, Cordova, Tennessee, 38018, United States\|Novartis Investigative Site, Johnson City, Tennessee, 37604, United States\|Novartis Investigative Site, Round Rock, Texas, 78681, United States\|Novartis Investigative Site, San Antonio, Texas, 78258, United States\|Novartis Investigative Site, Falls Church, Virginia, 22043, United States\|Novartis Investigative Site, Kirkland, Washington, 98034, United States\|Novartis Investigative Site, Seattle, Washington, 98122, United States\|Novartis Investigative Site, Spokane, Washington, 99202, United States\|Novartis Investigative Site, Tacoma, Washington, 98405, United States\|Novartis Investigative Site, Waukesha, Wisconsin, 53188, United States\|Novartis Investigative Site, Guaynabo, 00968, Puerto Rico Less <<
NCT04540861	Multiple Sclerosis		AVAILABLE	-	-

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed